Search

Your search keyword '"Krusius, T."' showing total 296 results
Start Over Author "Krusius, T."
296 results on '"Krusius, T."'

2. Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care

Author

Lieberman, L., Devine, D. V., Reesink, H. W., Panzer, S., Wong, J., Raison, T., Benson, S., Pink, J., Leitner, G. C., Horvath, M., Compernolle, V., Prado Scuracchio, P. S., Wendel, S., Delage, G., Nahirniak, S., Dongfu, X., Krusius, T., Juvonen, E., Sainio, S., Cazenave, J.-P., Guntz, P., Kientz, D., Andreu, G., Morel, P., Seifried, E., Hourfar, K., Lin, C. K., OʼRiordan, J., Raspollini, E., Villa, S., Rebulla, P., Flanagan, P., Teo, D., Lam, S., Ang, A. L., Lozano, M., Sauleda, S., Cid, J., Pereira, A., Ekermo, B., Niederhauser, C., Waldvogel, S., Fontana, S., Desborough, M. J., Pawson, R., Li, M., Kamel, H., Busch, M., Qu, L., and Triulzi, D.

Published
2014

4. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. (Inflammatory Bowel Disease)

Author

Helio, T., Halme, L., Lappalainen, M., Fodstad, H., Paavola-Sakki, P., Turunen, U., Farkkila, M., Krusius, T., and Kontula, K.

Subjects
Ulcerative colitis -- Genetic aspects, Genes -- Abnormalities -- Genetic aspects, Heredity -- Abnormalities -- Genetic aspects, Crohn's disease -- Genetic aspects, Health, Genetic aspects, Abnormalities
Abstract

Background: Variants of the caspase activating recruitment domain 15/nucleotide oligomerisatian domain 2 (CARD15/NOD2) gene have been associated with susceptibility to Crohn's disease (CD). Aim: Our aim was to evaluate the [...]

Published
2003

5. Measures to prevent transfusion-related acute lung injury (TRALI)

Author

Reesink, H. W., Lee, J., Keller, A., Dennington, P., Pink, J., Holdsworth, R., Schennach, H., Goldman, M., Petraszko, T., Sun, J., Meng, Y., Qian, K., Rehacek, V., Turek, P., Krusius, T., Juvonen, E., Tiberghien, P., Legrand, D., Semana, G., Muller, J. Y., Bux, J., Reil, A., Lin, C. K., Daly, H., McSweeney, E., Porretti, L., Greppi, N., Rebulla, P., Okazaki, H., Sánchez-Guerrero, S. A., Baptista-González, H. A., Martínez-Murillo, C., Guerra-Márquez, A., Rodriguez-Moyado, H., Middelburg, R. A., Wiersum-Osselton, J. C., Brand, A., van Tilburg, C., Dinesh, D., Dagger, J., Dunn, P., Brojer, E., Letowska, M., Maslanka, K., Lachert, E., Uhrynowska, M., Zhiburt, E., Palfi, M., Berlin, G., Frey, B. M., Rovira, Puig L., Muñiz-Diaz, E., Castro, E., Chapman, C., Green, A., Massey, E., Win, N., Williamson, L., Silliman, C. C., Chaffin, D. J., Ambruso, D. R., Blumberg, N., Tomasulo, P., Land, K. J., Norris, P. J., Illoh, O. C., Davey, R. J., Benjamin, R. J., Eder, A. F., McLaughlin, L., Kleinman, S., and Panzer, S.

Published
2012
Full Text
View/download PDF

6. Prion reduction of red-blood-cells

Author

Coste, J., Prowse, C., Grabmer, C., Schennach, H., Prado Scuracchio, Santos P., Wendel, S. N., Germain, M., Delage, G., Krusius, T., Ekblom-Kullberg, S., Tiberghien, P., O’Riordan, J., Murphy, W. G., Flesland, ., Turner, M., Williamson, L., Gregori, L., Epstein, J., Asher, D., Panzer, S., and Reesink, H. W.

Published
2012
Full Text
View/download PDF

9. New cellular therapies: Is there a role for transfusion services?

Author

Reesink, H. W., Panzer, S., Dettke, M., Gabriel, C., Lambermont, M., Deneys, V., Sondag, D., Dickmeiss, E., Fischer-Nielsen, A., Korhonen, M., Krusius, T., Ali, A., Tiberghien, P., Schrezenmeier, H., Tonn, T., Seifried, E., Klüter, H., Politis, C., Stavropoulou-Gioka, A., Parara, M., Flesland, Ø., Nascimento, F., Balint, B., Marin, P., Bart, T., Chen, F. E., and Pamphilon, D. H.

Published
2009
Full Text
View/download PDF

10. Neonatal transfusions

Author

New, H. V., Stanworth, S. J., Engelfriet, C. P., Reesink, H. W., McQuilten, Z. K., Savoia, H. F., Wood, E. M., Olyntho, S., Trigo, F., Wendel, S., Lin, Y., Hume, H., Petäjä, J., Krusius, T., Villa, S., Ghirardello, S., von Lindern, J., Brand, A., Hendrickson, J. E., Josephson, C. D., Strauss, R. G., Luban, N. L. C., and Paul, W.

Published
2009

11. Biobanks of blood from donors and recipients of blood products

Author

Reesink, H. W., Engelfriet, C. P., Hyland, C. A., Coghlan, P., Tait, B., Wsolak, M., Keller, A. J., Henn, G., Mayr, W. R., Thomas, I., Osselaer, J.-C., Lambermont, M., Beaten, M., Wendel, S., Qiu, Y., Georgsen, J., Krusius, T., Mäki, T., Andreu, G., Morel, P., Lefrère, J.-J., Rebulla, P., Giovanelli, S., Butti, B., Lecchi, L., Mozzi, F., van Hilten, J. A., Zwaginga, J. J., Flanagan, P., Flesland, Ø., Brojer, E., Łętowska, M., Åkerblom, O., Norda, R., Prowse, C., Dow, B., Jarvis, L., Davidson, F., Kleinman, S., Bianco, C., Stramer, S. L., Dodd, R. Y., and Busch, M. P.

Published
2008

12. Occult hepatitis B infection in blood donors

Author

Reesink, H. W., Engelfriet, C. P., Henn, G., Mayr, W. R., Delage, G., Bernier, F., Krusius, T., Assal, A., Gallian, P., Corbi, C., Morel, P., David, B., De Micco, P., Murokawa, H., Yugi, H., Hino, S., Tadokoro, K., Flesland, Ø., Brojer, E., Łętowska, M., Olim, G., Nascimento, F., Gonęalves, H., Castro, L., Morais, M., Stezinar, S. L., Alvarez, M., Sauleda, S., González, R., Niederhauser, C., Stolz, M., Allain, J.-P., Owusu-Ofori, S., Eglin, R., Stramer, S., Busch, M., Strong, D. M., Epstein, J., and Biswas, R.

Published
2008

22. Red blood cell transfusion in southern Finland from 2011 to 2016: a quality audit.

Author

Laurén, E., Vikatmaa, L., Kerkelä, E., Kivipuro, T., Krusius, T., Syrjälä, M., Ihalainen, J., and Pettilä, V.

Subjects
RED blood cell transfusion, POPULATION, ERYTHROCYTES, POPULATION aging
Abstract

SUMMARY: Objectives: The current trends in RBC use and pre‐ and post‐transfusion Hb levels were analysed to improve practice and to provide international comparison. Background: Indications for RBC transfusion have changed with growing scientific evidence. The lowest acceptable haemoglobin (Hb) level has decreased, and transfusing single units instead of pairs has become the new standard. Evidence‐based guidelines and patient blood management (PBM) programmes increase clinician awareness of rational RBC use. In Finland, however, no formal PBM programme has been established to date. Methods: The study was registry‐based, retrospective and observational. All RBC transfusions for adult patients from 2011 to 2016 in the southern region of Finland were analysed. Results: RBC usage decreased from 34·9 to 27·5 units per 1000 population (P < 0·001). The percentage of single‐unit transfusions increased from 57·9 to 66·7%, and the median pre‐ and post‐transfusion Hb levels decreased from 8·4 to 8·2 g dL−1 (P < 0·001) and 9·9 to 9·6 g dL−1 (P < 0·001), respectively. The proportion of transfusions with pre‐transfusion Hb ≥ 9·0 g dL−1 decreased during the study period but remained high, being 29·5% in 2011 and still 25·2% in 2016. Conclusions: Consumption of RBCs has decreased despite aging population and increasing healthcare performance demands. The results indicate more rational and evidence‐based RBC use. Nevertheless, the transfusion rate and pre‐ and post‐transfusion Hb are still sufficiently high to enable more restrictive transfusion practice. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

25. Consequences of nucleic acid amplification testing for blood transfusion centres

Author

C. P. Engelfriet, Diekamp U, H. W. Reesink, Lankinen M, C. Martin-Vega, Vrielink H, G. Sirchia, Hernândez Jm, Flanagan P, Jay S. Epstein, Edward Tabor, John A. J. Barbara, Peter Gill, Krusius T, F. Mozzi, Daniele Prati, Roger Y. Dodd, Michael P. Busch, and Other departments

Subjects
medicine.medical_specialty, Blood transfusion, business.industry, medicine.medical_treatment, Hematology, General Medicine, Virology, Biological fluid, law.invention, Surgery, law, Nucleic acid, medicine, business, Polymerase chain reaction, Blood bank
Published
1998

26. Vox sanguinis / Occult hepatitis B infection in blood donors

Author

Reesink, H. W., Engelfriet, C. P., Henn, G., Mayr, Wolfgang, Delage, G., Bernier, F., Krusius, T., Assal, A., Gallian, P., Corbi, C., Morel, P., David, B., De Micco, P., Murokawa, H., Yugi, H., Hino, S., Tadokoro, K., Flesland, Ø., Brojer, E., Letowska, M., Olim, G., Nascimento, F., Gonçalves, H., Castro, L., Morais, M., Stezinar, S. L., Alvarez, M., Sauleda, S., González, R., Niederhauser, C., Stolz, M., Allain, J. -P, Owusu-Ofori, S., Eglin, R., Stramer, S., Busch, M., Strong, D. M., Epstein, J., and Biswas, R.

Published
2008

27. Vox sanguinis / Biobanks of blood from donors and recipients of blood products

Author

Reesink, H. W., Engelfriet, C. P., Hyland, C. A., Coghlan, P., Tait, B., Wsolak, M., Keller, A. J., Henn, G., Mayr, Wolfgang, Thomas, I., Osselaer, J. C., Lambermont, M., Beaten, M., Amorim, L., Qiu, Y., Georgsen, J., Krusius, T., Maki, T., Andreu, G., Morel, P., Lefrere, J. J., Rebulla, P., Giovanelli, S., Butti, B., Lecchi, L., Mozzi, F., van Hilten, J. A., Zwaginga, J. J., Flanagan, P., Flesland, O., Brojer, E., Letowska, M., Akerblom, O., Norda, R., Prowse, C., Dow, B., Jarvis, L., Davidson, F., Kleinman, S., Bianco, C., Stramer, S. L., Dodd, R. Y., and Busch, M. P.

Published
2008

28. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003

Author

Coste, J., Reesink, H. W., Engelfriet, C. P., Laperche, S., Brown, S., Busch, M. P., Cuijpers, H. T., Elgin, R., Ekermo, B., Epstein, J. S., Flesland, O., Heier, H. E., Henn, G., Hernandez, J. M., Hewlett, I. K., Hyland, C., Keller, A. J., Krusius, T., Levicnik-Stezina, S., Levy, G., Lin, C. K., Margaritis, A. R., Muylle, L., Niederhauser, C., Neiderhauser, C., Pastila, S., Pillonel, J., Pineau, J., van der Poel, C. L., Politis, C., Roth, W. K., Sauleda, S., Seed, C. R., Sondag-Thull, D., Stramer, S. L., Strong, M., Vamvakas, E. C., Velati, C., Vesga, M. A., Zanetti, A., AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, and Other departments

Published
2005

30. Single founder mutation (W380G) in type II protein C deficiency in Finland

Author

Levo A, Kuismanen K, Holopainen P, Vahtera E, Rasi V, Krusius T, and Jukka Partanen

Subjects
Family Health, Gene Frequency, Haplotypes, Chromosome Mapping, Humans, Point Mutation, Protein C Deficiency, Topography, Medical, Conserved Sequence, Finland, Founder Effect
Abstract

The present study investigated the genetic basis for type II protein C deficiency in Finland, where this form has an unusually high incidence. We demonstrated that, first, a single novel mutation W380G in the protein C gene (PROC) explained 25/26 index patients, estimated to represent two thirds of all families with type II deficiency in Finland. Second, extended chromosomal conservation, i.e. a specific haplotype, around the W380G mutation was indicated in unrelated patients. Third, a local geographical origin for the W380G mutation was suggested by genealogical data. These results are in contrast to the heterogeneity in type II protein C deficiency elsewhere, but closely parallel disorders of the Finnish disease heritage. The high frequency of the type II disease can be explained by founder effect and subsequent enrichment of a single mutation in Finland. The present study also provided a simple means for genetic diagnosis of this disease and the genetic test can be included in the routine screenings in this population.

Published
2000

31. Evaluation of soluble glycoprotein V as an in vitro quality marker for platelet concentrates: a correlation study between in vitro platelet quality markers and the effect of storage medium.

Author

Kiminkinen, L. K. M., Krusius, T., and Javela, K. M.

Subjects
*GLYCOPROTEIN analysis, *BLOOD platelet activation, *BIOMARKERS, *IN vitro studies, BLOOD platelet examination
Abstract

Background and objectives Extent of shape change ( ESC), hypotonic shock response ( HSR), the adhesive glycoprotein CD62P and lactate have been widely used as in vitro quality makers of platelet concentrates. Our aim was to evaluate soluble glycoprotein V ( sGPV) as a platelet in vitro activation marker for platelet concentrates. Data were obtained from different validations during a twelve-year period. Materials and methods Platelet concentrates stored in PAS B, PAS E with 20-35% plasma carry-over or in plasma were prepared either from buffy coats or collected by apheresis. The samples were analysed up to day seven using sGPV, ESC, HSR, CD62P and lactate in addition to normal quality control assays. Results sGPV correlated statistically significantly with ESC, HSR, CD62P and lactate in platelet concentrates stored in PASs. Conclusion We propose that quantitative sGPV which is calculated per platelet number could be used as the first choice in vitro platelet activation marker in validations and monitoring platelet production processes. sGPV could also be a promising alternative to platelet activation assays used in interlaboratory comparisons of the quality of platelet concentrates. Quantitative lactate and lactate production rate can be used to evaluate the quality of platelets concentrates during storage. However, the formation of lactate depends on the platelet count and the amount of glucose in the product making the comparison more difficult. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

33. Geographical distribution of hepatitis C virus genotypes in blood donors:an international collaborative survey

Author

McOmish, F, Yap, P L, Dow, B C, Follett, E A, Seed, C, Keller, A J, Cobain, T J, Krusius, T, Kolho, E, Naukkarinen, R, Lin, C, Lai, C, Leong, S, Medgyesi, G A, Hejjas, M, Kiyokawa, H, Fukada, K, Cuypers, T, Saeed, A A, Alrasheed, A M, Lin, M, and Simmonds, Peter

Subjects
Base Sequence, Far East, Genotype, International Cooperation, Molecular Sequence Data, Genetic Variation, Blood Donors, Hepacivirus, Hepatitis C, Europe, Humans, RNA, Viral, Blood Transfusion, Egypt, Polymorphism, Restriction Fragment Length
Abstract

The frequency of infection with the six classified major genotypes of hepatitis C virus (HCV) was investigated in 447 infected volunteer blood donors from the following nine countries: Scotland, Finland, The Netherlands, Hungary, Australia, Egypt, Japan, Hong Kong, and Taiwan. Viral sequences in plasma from blood donors infected with HCV were amplified in the 5'-noncoding region and were typed by restriction fragment length polymorphism analysis. Electrophoresis of DNA fragments produced by cleavage with HaeIII-RsaI and ScrFI-HinfI allowed HCV types 1 (or 5), 2, 3, 4, and 6 to be identified. Further analysis with MvaI-HinfI allowed sequences of the type 5 genotype to be distinguished from sequences of the type 1 genotype. Types 1, 2, and 3 accounted for almost all infections in donors from Scotland, Finland, The Netherlands, and Australia. Types 2 and 3 were not found in the eastern European country (Hungary), where all but one of the donors were infected with type 1. Donors from Japan and Taiwan were infected only with type 1 or 2, while types 1, 2, and 6 were found in those from Hong Kong. HCV infection among Egyptians was almost always by type 4. Donors infected with HCV type 1 showed broad serological reactivity with all four antigens of the second generation Chiron RIBA-2 assay (Chiron Corporation, Emeryville, Calif.), while infection with divergent HCV genotypes elicited antibodies mainly reactive to c22-3 and c33c. Reactivities with antibodies 5-1-1 and c100-3 were infrequent and were generally weak, irrespective of the geographical origin of the donor. Because the envelope region of HCV is even more variable than the NS-4 region, it is likely that vaccines based on these proteins need to be multivalent and perhaps specifically adapted for different geographical regions.

Published
1994

34. Neonatal transfusions

Author

New, H. V., primary, Stanworth, S. J., additional, Engelfriet, C. P., additional, Reesink, H. W., additional, McQuilten, Z. K., additional, Savoia, H. F., additional, Wood, E. M., additional, Olyntho, S., additional, Trigo, F., additional, Wendel, S., additional, Lin, Y., additional, Hume, H., additional, Petäjä, J., additional, Krusius, T., additional, Villa, S., additional, Ghirardello, S., additional, Von Lindern, J., additional, Brand, A., additional, Hendrickson, J. E., additional, Josephson, C. D., additional, Strauss, R. G., additional, Luban, N. L. C., additional, and Paul, W., additional

Published
2008
Full Text
View/download PDF

36. Measures to prevent TRALI

Author

Engelfriet, C.P., primary, Reesink, H. W., additional, Wendel, S., additional, Biagini, S., additional, Trigo, F., additional, Fontão-Wendel, R., additional, Taaning, E., additional, Jørgensen, J., additional, Riisom, K., additional, Krusius, T., additional, Koskinen, S., additional, Kretschmer, V., additional, Karger, R., additional, Lawlor, E., additional, Okazaki, H., additional, Charlewood, R., additional, Brand, A., additional, Solheim, B. G., additional, Flesland, O., additional, Letowska, M., additional, Zupanska, B., additional, Muñiz-Diaz, E., additional, Nogués, N., additional, Senn, M., additional, Mansouri-Taleghani, B., additional, Chapman, C. E., additional, Massey, E., additional, Navarrete, C., additional, Stainsby, D., additional, Win, N., additional, Williamson, L. M., additional, Kleinman, S., additional, Kopko, P. M., additional, Silva, M., additional, Shulman, I., additional, Holness, L., additional, and Epstein, J. S., additional

Published
2007
Full Text
View/download PDF

37. International Forum: 1

Author

Coste, J., primary, Reesink, H. W., additional, Engelfriet, C. P., additional, Laperche, S., additional, Brown, S., additional, Busch, M. P., additional, Cuijpers, H. T., additional, Elgin, R., additional, Ekermo, B., additional, Epstein, J. S., additional, Flesland, O., additional, Heier, H. E., additional, Henn, G., additional, Hernandez, J. M., additional, Hewlett, I. K., additional, Hyland, C., additional, Keller, A. J., additional, Krusius, T., additional, Levicnik-Stezina, S., additional, Levy, G., additional, Lin, C. K., additional, Margaritis, A. R., additional, Muylle, L., additional, Neiderhauser, C., additional, Pastila, S., additional, Pillonel, J., additional, Pineau, J., additional, van der Poel, C. L., additional, Politis, C., additional, Roth, W. K., additional, Sauleda, S., additional, Seed, C. R., additional, Sondag-Thull, D., additional, Stramer, S. L., additional, Strong, M., additional, Vamvakas, E. C., additional, Velati, C., additional, Vesga, M. A., additional, and Zanetti, A., additional

Published
2005
Full Text
View/download PDF

38. Author's reply

Author

Helio, T., Lappalainen, M., Fodstad, H., Paavola-Sakki, P., Turunen, U., Farkkila, M., Kontula, K., Halme, L., and Krusius, T.

Subjects
Health
Abstract

Gyorffy et al addressed the relevant issue of deviation of biallelic genotype distributions from Hardy-Weinberg equilibrium and the interpretation of case control studies. They identified several papers that had been [...]

Published
2004

47. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region

Author

Davidson, F., primary, Simmonds, P., additional, Ferguson, J. C., additional, Jarvis, L. M., additional, Dow, B. C., additional, Follett, E. A. C., additional, Seed, C. R. G., additional, Krusius, T., additional, Lin, C., additional, Medgyesi, G. A., additional, Kiyokawa, H., additional, Olim, G., additional, Duraisamy, G., additional, Cuypers, T., additional, Saeed, A. A., additional, Teo, D., additional, Conradie, J., additional, Kew, M. C., additional, Lin, M., additional, Nuchaprayoon, C., additional, Ndimbie, O. K., additional, and Yap, P. L., additional

Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results